Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.
Adult
Aged
Algorithms
Autoantibodies
/ metabolism
C-Peptide
/ metabolism
Consensus Development Conferences as Topic
Diabetes Mellitus, Type 2
/ drug therapy
Female
Genetic Predisposition to Disease
Glutamate Decarboxylase
/ metabolism
Humans
Hypoglycemic Agents
/ therapeutic use
International Cooperation
Latent Autoimmune Diabetes in Adults
/ drug therapy
Male
Middle Aged
Practice Guidelines as Topic
Sulfonylurea Compounds
/ therapeutic use
Journal
Diabetes
ISSN: 1939-327X
Titre abrégé: Diabetes
Pays: United States
ID NLM: 0372763
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
22
04
2020
accepted:
09
07
2020
pubmed:
28
8
2020
medline:
26
1
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
A substantial proportion of patients with adult-onset diabetes share features of both type 1 diabetes (T1D) and type 2 diabetes (T2D). These individuals, at diagnosis, clinically resemble T2D patients by not requiring insulin treatment, yet they have immunogenetic markers associated with T1D. Such a slowly evolving form of autoimmune diabetes, described as latent autoimmune diabetes of adults (LADA), accounts for 2-12% of all patients with adult-onset diabetes, though they show considerable variability according to their demographics and mode of ascertainment. While therapeutic strategies aim for metabolic control and preservation of residual insulin secretory capacity, endotype heterogeneity within LADA implies a personalized approach to treatment. Faced with a paucity of large-scale clinical trials in LADA, an expert panel reviewed data and delineated one therapeutic approach. Building on the 2020 American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) consensus for T2D and heterogeneity within autoimmune diabetes, we propose "deviations" for LADA from those guidelines. Within LADA, C-peptide values, proxy for β-cell function, drive therapeutic decisions. Three broad categories of random C-peptide levels were introduced by the panel:
Identifiants
pubmed: 32847960
pii: dbi20-0017
doi: 10.2337/dbi20-0017
pmc: PMC7809717
doi:
Substances chimiques
Autoantibodies
0
C-Peptide
0
Hypoglycemic Agents
0
Sulfonylurea Compounds
0
Glutamate Decarboxylase
EC 4.1.1.15
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2037-2047Informations de copyright
© 2020 by the American Diabetes Association.
Références
Diabetes. 2010 Feb;59(2):416-22
pubmed: 19864397
Diabetes Metab Res Rev. 2020 Jul;36(5):e3298
pubmed: 32043288
J Clin Endocrinol Metab. 2014 May;99(5):E876-80
pubmed: 24432999
Diabet Med. 2016 Nov;33(11):1554-1558
pubmed: 27100275
Nat Rev Endocrinol. 2017 Nov;13(11):674-686
pubmed: 28885622
J Diabetes Complications. 2005 Jul-Aug;19(4):238-46
pubmed: 15993359
N Engl J Med. 2017 Dec 14;377(24):2337-2348
pubmed: 28899222
Diabetes Care. 2020 Feb;43(2):418-425
pubmed: 31843946
Diabetes Obes Metab. 2019 Sep;21(9):2115-2122
pubmed: 31099472
Lancet. 2014 Mar 22;383(9922):1084-94
pubmed: 24315621
Diabetes Care. 2016 Nov;39(11):1932-1939
pubmed: 27573939
Diabetes Care. 2015 Jan;38(1):16-21
pubmed: 25336751
Diabetes Ther. 2017 Oct;8(5):1123-1134
pubmed: 28929327
Diabetes Care. 2018 Sep;41(9):1938-1946
pubmed: 30026335
Eur J Endocrinol. 2011 Feb;164(2):239-45
pubmed: 21088056
Diabetes Care. 1999 Aug;22(8):1347-53
pubmed: 10480781
Diabetes. 2013 Feb;62(2):543-50
pubmed: 23086039
Diabetes. 2008 May;57(5):1433-7
pubmed: 18310307
Diabetes Care. 2000 May;23(5):589-94
pubmed: 10834414
PLoS One. 2015 Aug 07;10(8):e0131837
pubmed: 26252955
Diabetes Care. 2013 Apr;36(4):908-13
pubmed: 23248199
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3265-3278
pubmed: 30938764
World J Diabetes. 2014 Aug 15;5(4):505-10
pubmed: 25126396
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32307525
Diabetes. 1993 Feb;42(2):359-62
pubmed: 8425674
Clin Chem. 2019 Sep;65(9):1141-1152
pubmed: 31409598
Trends Endocrinol Metab. 2018 Sep;29(9):638-650
pubmed: 30041834
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4815-4826
pubmed: 31125083
BMJ Open Diabetes Res Care. 2015 Jun 25;3(1):e000076
pubmed: 26157582
J Clin Endocrinol Metab. 2012 Oct;97(10):3759-65
pubmed: 22865904
Diabetes. 2008 May;57(5):1276-83
pubmed: 18332100
Diabetologia. 2018 Jul;61(7):1644-1649
pubmed: 29619531
Diabetologia. 2017 Sep;60(9):1594-1600
pubmed: 28770327
Diabetes. 1986 Feb;35(2):237-41
pubmed: 3510930
BMC Med. 2019 Aug 23;17(1):165
pubmed: 31438962
Diabetes Metab Res Rev. 2016 Mar;32(3):289-96
pubmed: 26385269
Diabetes Res Clin Pract. 2009 Jan;83(1):54-60
pubmed: 19008007
Diabetes Care. 2019 Aug;42(8):1414-1421
pubmed: 31152121
Diabetes Care. 2016 Feb;39(2):250-7
pubmed: 26242184
Diabetes Care. 2015 Mar;38(3):476-81
pubmed: 25519448
Diabetes Care. 2019 Jun;42(6):1147-1154
pubmed: 30728224
Curr Diabetes Rev. 2019;15(3):178-187
pubmed: 30009710
Diabetologia. 2014 Sep;57(9):1859-68
pubmed: 24906951
Diabetologia. 2009 Jul;52(7):1363-8
pubmed: 19404608
Diabetes Care. 2007 Apr;30(4):932-8
pubmed: 17392553
Diabetes Care. 2003 Mar;26(3):832-6
pubmed: 12610045
Diabetologia. 2005 Apr;48(4):695-702
pubmed: 15729570
Lancet Diabetes Endocrinol. 2020 Mar;8(3):206-215
pubmed: 32032540
Diabetes Care. 2000 Nov;23(11):1707-8
pubmed: 11092301
Diabetes Care. 2018 Dec;41(12):2560-2569
pubmed: 30287422
Diabetologia. 2012 May;55(5):1310-8
pubmed: 22297581
Diabetes Care. 2014;37(1):e11-2
pubmed: 24356601
Diabetologia. 2019 Mar;62(3):399-407
pubmed: 30594957
Diabetes Care. 1994 Oct;17(10):1214-9
pubmed: 7821148
Front Physiol. 2019 Mar 26;10:320
pubmed: 30971952
Diabetes. 1999 Jan;48(1):150-7
pubmed: 9892237
Diabetes Obes Metab. 2018 Jun;20(6):1490-1498
pubmed: 29377522
Eur J Endocrinol. 2014 Dec;171(6):697-704
pubmed: 25213702
Diabetes Care. 2018 Dec;41(12):2552-2559
pubmed: 30352894
Ann N Y Acad Sci. 2003 Nov;1005:362-9
pubmed: 14679093
Diabetes Care. 2017 Apr;40(4):561-568
pubmed: 28174261
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD006165
pubmed: 21901702
Diabetes Care. 2020 Jan;43(1):5-12
pubmed: 31753960
Diabetes. 2004 May;53(5):1293-302
pubmed: 15111499
Diabetes Care. 2018 Sep;41(9):1981-1990
pubmed: 29937431
Diabetes Obes Metab. 2019 Apr;21(4):893-902
pubmed: 30471182
Diabetes Care. 2019 Aug;42(8):1357-1364
pubmed: 31167894
J Clin Endocrinol Metab. 2008 Jun;93(6):2115-21
pubmed: 18397986
Diabetes Care. 2020 Feb;43(2):487-493
pubmed: 31857443
Diabetes Care. 2015 Dec;38(12):2258-65
pubmed: 26486192
Diabetes Obes Metab. 2015 Oct;17(10):928-35
pubmed: 26080652
Diabetologia. 2019 Jan;62(1):33-40
pubmed: 30167735
Diabetes. 1996 May;45(5):622-6
pubmed: 8621013
Diabetologia. 1983 Nov;25(5):392-5
pubmed: 6360778
Diabetes Care. 2009 Jan;32(1):160-4
pubmed: 18945926
Diabetes Obes Metab. 2019 Oct;21(10):2219-2227
pubmed: 31148332
Diabet Med. 2010 Jun;27(6):701-4
pubmed: 20546291
Diabetes Care. 2010 Sep;33(9):2062-4
pubmed: 20805278
BMJ Open. 2019 Sep 26;9(9):e031586
pubmed: 31558459
Diabetes Care. 2010 Jan;33(1):104-8
pubmed: 19808923
Diabetes Obes Metab. 2020 Mar;22(3):427-433
pubmed: 31858718
Diabetologia. 2020 Mar;63(3):588-596
pubmed: 31768570
Diabetes Care. 2018 Nov;41(11):2396-2403
pubmed: 30254083
Rev Endocr Metab Disord. 2003 Sep;4(3):233-41
pubmed: 14501174
BMC Endocr Disord. 2015 Jan 09;15:1
pubmed: 25572256
Diabetes Care. 2006 May;29(5):970-5
pubmed: 16644622
Eur J Endocrinol. 2010 Oct;163(4):541-9
pubmed: 20603341
Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):203-8
pubmed: 15386806
Lancet. 1997 Nov 1;350(9087):1288-93
pubmed: 9357409